Literature DB >> 16130188

Immunomodulatory function of orally administered thymosin alpha1.

Xiang-Ming Chen1, Han-Liang Jiang, Lin-Fu Zhou, Xiao-Ping Pan, Zhong-Rong Hu, Rong-Hua Liu, Xiao-Ming Chen, Zhi Chen.   

Abstract

OBJECTIVE: To investigate the immunological function of a yeast expression system for thymosin alpha1 (Talpha1).
METHODS: A constructed Talpha1 yeast expression system was used to investigate the immunological function of orally administered Talpha1. Dried yeast containing three different concentration of Talpha1 was fed to normal Balb/c mice and other Balb/c mice whose immunities were inhibited in advance by cyclophosphamide. Synthesized Talpha1 peptide was used as positive control and dried yeast with empty plasmid was used as negative control. CD4(+) and CD8(+) levels were detected by flow cytometry assay. TNF-alpha, IFN-gamma, IL-2, IL-6 and IL-10 levels were detected by liquid chip.
RESULTS: In normal Balb/c mice or immune inhibition Balb/c mice, CD8(+) levels were significantly increased. Especially in immune inhibition Balb/c mice, CD8(+) levels in synthesized Talpha1 group (18.77%+/-4.72%), small dose group (13.48%+/-6.17%) and large dose group (22.74%+/-1.09%) were significantly higher than that in empty yeast control group (7.49%+/-2.14%).
CONCLUSION: Orally administered Talpha1 has its certain immunomodulatory function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16130188      PMCID: PMC1389904          DOI: 10.1631/jzus.2005.B0873

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  5 in total

Review 1.  Antiviral therapy of HBV- and HCV-induced liver cirrhosis.

Authors:  C Zavaglia; A Airoldi; G Pinzello
Journal:  J Clin Gastroenterol       Date:  2000-04       Impact factor: 3.062

Review 2.  Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application.

Authors:  E Garaci; F Pica; G Rasi; C Favalli
Journal:  Int J Immunopharmacol       Date:  2000-12

3.  The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results.

Authors:  P Kullavanuaya; S Treeprasertsuk; D Thong-Ngam; K Chaermthai; S Gonlachanvit; P Suwanagool
Journal:  J Med Assoc Thai       Date:  2001-06

4.  In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C.

Authors:  P Andreone; C Cursaro; A Gramenzi; M Margotti; E Ferri; S Talarico; M Biselli; F Felline; C Tuthill; E Martins; G Gasbarrini; M Bernardi
Journal:  J Viral Hepat       Date:  2001-05       Impact factor: 3.728

5.  Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B.

Authors:  Murat Saruc; Nuri Ozden; Nurten Turkel; Semin Ayhan; Lynette M Hock; Isil Tuzcuoglu; Hakan Yuceyar
Journal:  J Pharm Sci       Date:  2003-07       Impact factor: 3.534

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.